Skip to content
  1. Home
  2. Business

Medicago reports promising early Phase 1 test results of possible COVID-19 vaccine

Medicago plans to proceed with next phase of clinical trial
The Canadian Press
23284298_web1_201110-RDA-Medicago-reports-promising-early-Phase-1-test-results-of-possible-COVID-19-vaccine-coronavirus_1
A vial of a plant-derived COVID-19 vaccine candidate, developed by Medicago, is shown in Quebec City on Monday, July 13, 2020 as part of the company’s Phase 1 clinical trials in this handout photo. Medicago says it has received promising early test results for its plant-derived vaccine for COVID-19. THE CANADIAN PRESS/HO, Medicago

QUEBEC — Medicago says it has received promising early test results for its plant-derived vaccine for COVID-19.

The Quebec City-based company says interim results of a Phase 1 clinical trial found that 100 per cent of subjects developed a promising antibody response after two doses of its COVID-19 vaccine candidate.

Medicago says the side effects were generally mild to moderate and short in duration.

The Phase 1 clinical trial was a randomized, partially blinded study of 180 healthy people.

Based on the Phase 1 data, Medicago plans to proceed with a Phase 2/3 clinical trial for its COVID-19 vaccine candidate, subject to regulatory approval.

The federal government has signed a $173-million contract with Medicago to secure the rights to buy 76 million doses of its vaccine, should it meet health and safety standards.

This report by The Canadian Press was first published Nov. 10, 2020.